-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎ WuXi AppTec content team editor May 4, 2021, ImmunityBio announced that its IL-15 super agonist complex Anktiva (N-803) combined with anti-CD20 monoclonal antibody therapy Rituxan (rituximab), in A 78% complete remission rate was achieved when treating patients with CD20 sensitive indolent non-Hodgkin lymphoma (iNHL, indolent non-Hodgkin lymphoma).
The results of this phase 1 clinical trial were published in Clinical Cancer Research.
Malignant tumors formed by cancerous changes in lymphocytes are called lymphomas.
According to different sources of tumor cells, they can be divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma.
According to tumor cell proliferation speed and clinical characteristics, non-Hodgkin's lymphoma can be divided into three types, namely slow-growing indolent lymphoma, fast-growing aggressive lymphoma and very fast-growing highly aggressive lymphoma.
Indolent lymphoma, although the tumor grows slowly, is relatively insensitive to chemotherapy, is often incurable with ordinary therapies, and can become more aggressive over time.
ImmunityBio's Anktiva is a potential "first-in-class" IL-15 super agonist complex.
It consists of an IL-15 mutant (IL-15N72D) combined with a fusion protein composed of IL-15 receptor α and the Fc end of IgG1, which promotes natural killer cells (NK, natural killer) and CD8-positive T cells Amplify to produce anti-cancer activity.
Compared with the natural non-composite IL-15 in the body, Anktiva's pharmacokinetic properties have been improved, and it can stay in the lymph node tissue for a longer period of time and has a higher anti-cancer activity.
It has achieved a 71% complete remission rate in phase 2/3 clinical trials for the treatment of patients with specific bladder cancer.
▲The mechanism of action of Anktiva (picture source: ImmunityBio's official website) CD20 monoclonal antibody can specifically bind to the CD20 protein on B cells, and through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), direct apoptosis, antibody-mediated phagocytosis (ADCP) and other mechanisms to kill lymphoma cancer cells derived from B cells or B cells in the immune system.
This ongoing study aims to evaluate the efficacy of Anktiva combined with Rituxan in the treatment of iNHL patients, explore the potential of Anktiva to enhance tumor targeting of anti-CD20 therapeutic antibodies, and determine the safety and effectiveness of subcutaneous and intravenous administration.
The results of the test showed that the enrolled patients tolerated the combination therapy of Anktiva and Rituxan well.
Among patients who were sensitive to anti-CD20 mAb, the total remission rate of the subcutaneous administration group was 78% (7/9), and all patients who achieved remission achieved complete remission.
Among the 5 patients who were resistant to anti-CD20 monoclonal antibodies, the total remission rate of the combination therapy was 40% (2/5), including 1 patient in complete remission.
The researchers observed that the disease did not progress in 8 of the 12 patients for 18-24 months.
In related immunological experiments, Anktiva combined with Rituxan induced the expansion, activation and regulation of NK cells and CD8-positive T cells, while having little effect on CD4-positive T cells and regulatory T cells.
Dr.
Todd Fehniger of Washington University School of Medicine in St Louis said: “These encouraging data indicate that ImmunityBio’s IL-15 super agonist, Anktiva, has the potential to enhance anti-CD20 therapeutic antibodies.
active. We believe that the excellent safety observed in the subcutaneous injection cohort, combined with its convincing efficacy, supports further exploration of this treatment option in iNHL patients.
The resulting transformational immunological data showed the activation of important cell populations including NK cells and CD8-positive T cells, which is the key to driving the immunotherapy response.
Taken together, these results indicate that Anktiva may have broad potential to enhance the activity of therapeutic monoclonal antibodies in a variety of tumor types.
"Reference: [1] ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients, May 5, 2021, from news/home/20210504005511/en Note: This article aims to introduce the progress of medical and health research and is not a recommendation
for treatment plans .
If you need guidance on treatment plans, please go to a regular hospital for treatment.
The results of this phase 1 clinical trial were published in Clinical Cancer Research.
Malignant tumors formed by cancerous changes in lymphocytes are called lymphomas.
According to different sources of tumor cells, they can be divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma.
According to tumor cell proliferation speed and clinical characteristics, non-Hodgkin's lymphoma can be divided into three types, namely slow-growing indolent lymphoma, fast-growing aggressive lymphoma and very fast-growing highly aggressive lymphoma.
Indolent lymphoma, although the tumor grows slowly, is relatively insensitive to chemotherapy, is often incurable with ordinary therapies, and can become more aggressive over time.
ImmunityBio's Anktiva is a potential "first-in-class" IL-15 super agonist complex.
It consists of an IL-15 mutant (IL-15N72D) combined with a fusion protein composed of IL-15 receptor α and the Fc end of IgG1, which promotes natural killer cells (NK, natural killer) and CD8-positive T cells Amplify to produce anti-cancer activity.
Compared with the natural non-composite IL-15 in the body, Anktiva's pharmacokinetic properties have been improved, and it can stay in the lymph node tissue for a longer period of time and has a higher anti-cancer activity.
It has achieved a 71% complete remission rate in phase 2/3 clinical trials for the treatment of patients with specific bladder cancer.
▲The mechanism of action of Anktiva (picture source: ImmunityBio's official website) CD20 monoclonal antibody can specifically bind to the CD20 protein on B cells, and through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), direct apoptosis, antibody-mediated phagocytosis (ADCP) and other mechanisms to kill lymphoma cancer cells derived from B cells or B cells in the immune system.
This ongoing study aims to evaluate the efficacy of Anktiva combined with Rituxan in the treatment of iNHL patients, explore the potential of Anktiva to enhance tumor targeting of anti-CD20 therapeutic antibodies, and determine the safety and effectiveness of subcutaneous and intravenous administration.
The results of the test showed that the enrolled patients tolerated the combination therapy of Anktiva and Rituxan well.
Among patients who were sensitive to anti-CD20 mAb, the total remission rate of the subcutaneous administration group was 78% (7/9), and all patients who achieved remission achieved complete remission.
Among the 5 patients who were resistant to anti-CD20 monoclonal antibodies, the total remission rate of the combination therapy was 40% (2/5), including 1 patient in complete remission.
The researchers observed that the disease did not progress in 8 of the 12 patients for 18-24 months.
In related immunological experiments, Anktiva combined with Rituxan induced the expansion, activation and regulation of NK cells and CD8-positive T cells, while having little effect on CD4-positive T cells and regulatory T cells.
Dr.
Todd Fehniger of Washington University School of Medicine in St Louis said: “These encouraging data indicate that ImmunityBio’s IL-15 super agonist, Anktiva, has the potential to enhance anti-CD20 therapeutic antibodies.
active. We believe that the excellent safety observed in the subcutaneous injection cohort, combined with its convincing efficacy, supports further exploration of this treatment option in iNHL patients.
The resulting transformational immunological data showed the activation of important cell populations including NK cells and CD8-positive T cells, which is the key to driving the immunotherapy response.
Taken together, these results indicate that Anktiva may have broad potential to enhance the activity of therapeutic monoclonal antibodies in a variety of tumor types.
"Reference: [1] ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients, May 5, 2021, from news/home/20210504005511/en Note: This article aims to introduce the progress of medical and health research and is not a recommendation
for treatment plans .
If you need guidance on treatment plans, please go to a regular hospital for treatment.
